ArticleEuropean journal of heart failure2024
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function.
Open access · hybridAbstract read
In one paragraph
Article in European journal of heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Brazilian guidelines for the pharmacological treatment of pulmonary hypertension. Official document of the Brazilian Thoracic Society based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.Respiratory research & clinical practice · 2026Guideline
- Diagnosis of Pulmonary Hypertension by Integrating Multimodal Data with a Hybrid Graph Convolutional and Transformer Network.Journal of imaging informatics in medicine · 2026Article
- Identification of pulmonary hypertension with pulmonary vascular surface volume ratio by non-contrast CT.BMC cardiovascular disorders · 2026Article
- Worldwide Epidemiology of Pulmonary Hypertension Associated With Left Heart Disease.Cardiology discovery · 2026Review
- Heart-Lung Interactions in Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction.Comprehensive physiology · 2026Review
- A hemodynamic and biomarker study of pulmonary hypertension associated with heart failure: DISCOVER PH-HF.Journal of cardiovascular medicine (Hagerstown, Md.) · 2026Article
- One Health Insights into Pulmonary Hypertension: Bridging Human and Canine Medicine.Veterinary sciences · 2026Review
- Hemodynamic Definitions, Phenotypes, Pathophysiology, and Evaluation of Pulmonary Hypertension Related to Left Heart Disease.Journal of cardiovascular development and disease · 2025Review
- Prognosis and Treatment With Phosphodiesterase 5 Inhibitors in Combined Post- and Precapillary Pulmonary Hypertension: A Propensity Score-Matched Analysis From the Hellenic Pulmonary Hypertension Registry.Pulmonary circulation · 2025Article
- Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling.World journal of cardiology · 2025Review
- "Form follows function": the developmental morphology of the cardiac atria.Physiological research · 2024Review
- Non-invasive prediction of pulmonary vascular disease-related exercise intolerance and survival in non-group 1 pulmonary hypertension.European journal of heart failure · 2024Article
- The pathophysiological approach: the best for phenotyping patients with pulmonary arterial hypertension: reply.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 20 institutions in 16 countries.
Pietro Ameri *Department of Internal Medicine, University of Genova, Genoa, Italy.
Valentina Mercurio *Department of Translational Medical Sciences, Interdepartmental Center for Clinical and Translational Research (CIRCET), and Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy.
Piero PolleselloContent and Communication, Branded Products, Orion Pharma, Espoo, Finland.
Markus S AnkerDeutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin (Campus CBF), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Berlin, Germany.
Johannes BacksInstitute of Experimental Cardiology, University Hospital Heidelberg, University of Heidelberg and DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, Germany.
Antoni Bayes-GenisHeart Institute, Hospital Universitari Germans Trias i Pujol, CIBERCV, Universitat Autònoma de Barcelona, Barcelona, Spain.
Barry A BorlaugDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Daniel BurkhoffCardiovascular Research Foundation, New York, NY, USA.
Sergio CaravitaDepartment of Management, Information and Production Engineering, University of Bergamo, Dalmine (BG), Italy.
Stephen Y ChanPittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine and UPMC, Pittsburgh, PA, USA.
Frances de ManPHEniX laboratory, Department of Pulmonary Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
George GiannakoulasFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aránzazu GonzálezProgram of Cardiovascular Diseases, CIMA Universidad de Navarra and IdiSNA, Pamplona, Spain.
Marco GuazziUniversity of Milan, Milan, Italy.
Paul M HassounDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Anna R HemnesDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Cristoph MaackComprehensive Heart Failure Center (CHFC) and Medical Clinic I, University Clinic Würzburg, Würzburg, Germany.
Brendan MaddenSt.Georges Hospital, London, UK.
Vojtech MelenovskyDepartment of Cardiology, Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic.
Oliver J MüllerDepartment of Internal Medicine V, University Hospital Schleswig-Holstein, and German Centre for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/Lübeck, Kiel, Germany.
Zoltan PappDivision of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Soni Savai PullamsettiDepartment of Internal Medicine and Excellence Cluster Cardio-Pulmonary Institute (CPI), Justus-Liebig University, Giessen, Germany.
Peter P RainerDivision of Cardiology, Medical University of Graz, Graz, Austria.
Margaret M RedfieldDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Stuart RichDivision of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Gabriele G SchiattarellaMax-Rubner Center (CMR), Department of Cardiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Hall SkaaraPulmonary Hypertension Association Europe, Vienna, Austria.
Kostantinos StellosDepartment of Cardiovascular Research, European Center for Angioscience (ECAS), Heidelberg University, Mannheim, Germany.
Ryan J TedfordDivision of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Thomas ThumInstitute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.
Jean Luc VachieryDepartment of Cardiology, Hopital Universitaire de Bruxelles Erasme, Brussels, Belgium.
Peter van der MeerDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Sophie Van LinthoutBerlin Institute of Health (BIH) at Charité, BIH Center for Regenerative Therapies, University of Medicine, Berlin, Germany.
Piotr PruszczykDepartment of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland.
Petar SeferovicUniversity of Belgrade Faculty of Medicine, Belgrade University Medical Center, Serbian Academy of Sciences and Arts, Belgrade, Serbia.
Andrew J S CoatsHeart Research Institute, Sydney, Australia.
Marco MetraCardiology. ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Giuseppe RosanoIRCCS San Raffaele, Rome, Italy.
Stephan RosenkranzDepartment of Cardiology and Cologne Cardiovascular Research Center (CCRC), Heart Center at the University Hospital Cologne, Cologne, Germany.
Carlo Gabriele TocchettiDepartment of Translational Medical Sciences, Interdepartmental Center for Clinical and Translational Research (CIRCET), and Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy.
Federico II University Hospital · ITHeidelberg University · DEMayo Clinic · USPulmonary Hypertension Association · USAristotle University of Thessaloniki · GRCardiovascular Research Foundation · USCentro de Investigación en Red en Enfermedades Cardiovasculares · ESComprehensive Cancer Center Mainfranken · DEDeutsches Herzzentrum der Charité · DEErasmus Hospital · BEGerman Centre for Cardiovascular Research · DEInstitute of Clinical and Experimental Medicine · CZIRCCS Ospedale San Raffaele · ITJohns Hopkins University · USJustus-Liebig-Universität Gießen · DEMax Delbrück Center · DEMedical University of Graz · ATMedical University of South Carolina · USMedical University of Warsaw · PLMedizinische Hochschule Hannover · DE
Funding
Defining the Complex Biology of the miR-130/301 Family in Pulmonary HypertensionR01HL124021 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHAN, STEPHEN Y · 2014 to 2025
$4.9MIron-Sulfur Deficiency as a Critical Pathogenic Cause of Pulmonary HypertensionR01HL122596 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHAN, STEPHEN Y · 2015 to 2024
$4.5MPulmonary Hypertension in Left Heart DiseaseR01HL162828 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2023 to 2026
$3.1MHL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4MMayo Clinic HeartShare Clinical CenterU01HL160226 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2021 to 2026
$1.8MAmerican Heart Association 18EIA33900027Dutch Heart Foundation Dekker senior post-doc 2018T059Dutch Heart Foundation, Dutch Federation of University Medical CentresEuropean Research Council under the European Union's Horizon 2020 research and innovation programme 759248European Union - Next Generation EUGerman Centre for Cardiovascular ResearchGerman Research Foundation DFG 394046768German Research Foundation DFG CRC1366 C07HORIZON Europe ERC DISSECT-HFHORIZON Europe ERC ERC CoG 101045236Italian Ministry of Health PNRR-MAD-2022-12376632Italian Ministry of Health RF-2016-02362988Ministry of Health of the Czech Republic NU22-02-00161Netherlands CardioVascular Research InitiativeNetherlands Organisation for Health Research and DevelopmentNHLBI NIH HHS R01 HL122596NHLBI NIH HHS R01 HL124021NHLBI NIH HHS R01 HL128526NHLBI NIH HHS R01 HL162828NHLBI NIH HHS U01 HL160226NIH HHS HL 122596NIH HHS R01 HL124021NIH HHS R01 HL128526NIH HHS R01 HL162828NIH HHS U01 HL160226Royal Netherlands Academy of Sciences CVON-2012-08 PHAEDRARoyal Netherlands Academy of Sciences CVON-2017-10 Dolphin-GenesisRoyal Netherlands Academy of Sciences CVON-2018-29 PHAEDRA-IMPACTthe National Institute for Research of Metabolic and Cardiovascular Diseases LX22NPO5104The Netherlands Organization for Scientific Research NWO-VIDI: 917.18.338United States Department of Defense W81XWH2210245
Abstract
Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH-LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre-clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early-stage development of candidate therapies for PH-LHF.
Indexed as
Heart FailureHypertension, PulmonaryPulmonary CirculationVentricular Function, RightHumansDrugHeart failurePulmonary hypertensionTherapyTranslational
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.